Roche CEO Thomas Schinecker Talks Blockbuster Cancer Pill, Earnings | Bloomberg Talks
Roche CEO Thomas Schinecker joins Bloomberg's "The Opening Trade" to discuss his company's earnings and the timeline for ...
Chief Executive Officer, Roche Group, Roche Holding
Search every verified Thomas Schinecker interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. In April 2026, Schinecker discussed Roche's first-quarter performance, noting 6% growth in constant exchange rates and 7% growth in the pharma division. He described the Swiss franc's appreciation as a factor that makes the numbers look different in Swiss francs, but added that the company's sales growth in US dollars was 9%. Schinecker characterized a cancer medicine as a "major blockbuster," citing data from the LidEra trial that he said showed the medicine reduced the risk of death or recurrence of the disease by more than 30% in an early setting. He stated that the US was "extremely fast" in granting access to the medicine and estimated it would take another year and a half to two years to see how other countries respond. In January 2026, Schinecker said that bureaucracy in Europe is a problem and that Europe should create an environment with less bureaucracy to enable faster growth. He stated that access to medicines in Switzerland is becoming more difficult, noting that twice as many medicines are approved in Germany as in Switzerland. In a November 2024 podcast, Schinecker said that the US has a better environment for startups and access to venture capital, which attracts talent and translates academic innovation into biotechs more than in Europe. He also said that developing a new medicine takes on average around 13 years and that only about one out of ten makes it from the beginning of development to launch.
Roche CEO Thomas Schinecker joins Bloomberg's "The Opening Trade" to discuss his company's earnings and the timeline for ...
2025 Earnings Conference Call. #earningscall #StockMarketNews #conferenceCall Earnings Call | Earnings Conference Call ...
Roche schaut auf ein erfolgreiches Geschäftsjahr 2025 zurück. Die eigenen Ziele hat der Pharmakonzern erfüllt und auch der Blick nach vorne verspricht weiteres Wachstum - insbesondere in China und USA. Mit Blick auf Europa vermisst Roche-CEO Schinecker eine klare Wachstumspolitik und sagt im Video-Interview mit AWP: "Die Bürokratie in Europa ist ein Problem". Was die Schweiz betrifft, stellt Schinecker fest, "dass der Zugang zu Medikamenten hier immer schwieriger wird." So seien etwa in Deutschland doppelt so viele Medikamente zugelassen wie in der Schweiz.
Roche CEO: Future of cancer treatment, AI in Medicine and Trial Challenges What's next for cancer treatment and personalized ...
The Basel-based pharmaceutical company Roche disappointed many stock market players with its figures for 2023. According to Roche CEO Thomas Schinecker, underlying growth was nevertheless strong. "Without Covid-19, we grew 8 percent," he emphasized in an interview with AWP Video. That the coronavirus effect would eventually be over was clear, but Roche had still grown even so. What the manager otherwise says about the outlook for 2024 and what he has to report about the business with new diet products, you can see in the AWP interview.
Sign in to search the full transcript archive, filter by topic, and access every quote from Thomas Schinecker.
The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →
Pro unlocks every transcript in full, plus unlimited search across every executive and company we cover.
50% off appliedPulling data at scale? The Data API gives you 30,000 transcripts a month over REST, MCP and JSON.
Compare all plans